论文部分内容阅读
对成人急性非淋巴细胞白血病(ANLL)和淋巴细胞白血病(ALL)分别用A(H)D和VDD(p)+M方案等诱导治疗,并根据化疗后骨髓白血病细胞减少程度个别化调整,初治ANLL和ALL的完全缓解(CR)率分别为0.8和0.72。及早用含第二线抗白血病药物的方案巩固。中高剂量Ara-C和MTX和ABMT的14例中,11例至今持续CR(CCR)。本方案毒性较大,特别对骨髓抑制显著,强化支持和对症治疗是必要的。
Adult Acute non-lymphocytic leukemia (ANLL) and lymphoblastic leukemia (ALL) were treated with A (H) D and VDD (p) + M regimens respectively and adjusted according to the degree of myeloid leukemia after chemotherapy. The complete remission (CR) rates for ANLL and ALL were 0.8 and 0.72, respectively. As soon as possible with the second line of anti-leukemia drugs to consolidate the program. Eleven of the 14 patients with moderate to high doses of Ara-C, MTX and ABMT continued CR (CCR). The program toxicity, especially for significant bone marrow suppression, enhanced support and symptomatic treatment is necessary.